Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.78 |
| ▸ | PIK3R1 | P27986 | 13/20 | 0.78 |
| ▸ | MTOR | P42345 | 5/20 | 0.78 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.78 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.78 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.78 |
| ▸ | JAK2 | O60674 | 1/20 | 0.78 |
| ▸ | JAK1 | P23458 | 1/20 | 0.78 |
| ▸ | JAK3 | P52333 | 1/20 | 0.78 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.46 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3653208 | 0.90 | PIK3CA (0.67) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| Vs-5584 SCHEMBL29376859 | 0.88 | PIK3CA (1.00) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| Vs-5584 SCHEMBL539098 | 0.88 | PIK3CA (1.00) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL3791135 | 0.86 | PIK3CA (0.77) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL7895963 | 0.85 | PIK3CA (0.76) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL7908617 | 0.85 | PIK3CA (0.76) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL7902204 | 0.83 | PIK3CA (0.76) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL7900637 | 0.83 | PIK3CA (0.71) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL7898323 | 0.80 | PIK3CA (0.68) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL7894820 | 0.80 | PIK3CA (0.71) | PIK3CAPIK3R1MTORPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180265512-A1 | FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-09-20 | — | — | US | disclosed |
| US-9957270-B2 | Fused pyrimidine-based hydroxamate derivatives | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-05-01 | — | — | US | disclosed |
| US-20170121332-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | CHEN DIZHONG (SG) | 2017-05-04 | — | — | US | disclosed |
| US-20170121332-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | CHEN DIZHONG (SG) | 2017-05-04 | — | — | US | disclosed |
| US-20170121332-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | CHEN DIZHONG (SG) | 2017-05-04 | — | — | US | disclosed |
| US-20170044162-A1 | Fused Pyrimidine-Based Hydroxamate Derivatives | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-02-16 | — | — | US | disclosed |
| EP-3116876-A1 | FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES | Agency For Science, Technology And Research (SG) | 2017-01-18 | — | — | EP | disclosed |
| US-20160207927-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | VERASTEM INC (US) | 2016-07-21 | — | — | US | disclosed |
| US-20160207927-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | VERASTEM INC (US) | 2016-07-21 | — | — | US | disclosed |
| US-20160207927-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | VERASTEM INC (US) | 2016-07-21 | — | — | US | disclosed |
| EP-2414362-B1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | VERASTEM INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2414362-B1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | VERASTEM INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-20120142683-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | S*BIO PTE LTD. (SG) | 2012-06-07 | — | — | US | disclosed |
| US-20120142683-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | S*BIO PTE LTD. (SG) | 2012-06-07 | — | — | US | disclosed |
| US-20120142683-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | S*BIO PTE LTD. (SG) | 2012-06-07 | — | — | US | disclosed |
| EP-2414362-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | S*BIO Pte Ltd (SG) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114494-A1 | 8-SUBSTITUTED-2-MORPHOLINO PURINES FOR USE AS PI3K AND/OR MTOR INHIBITORS IN THE TREATMENT OF PROLIFERATIVE DISORDERS | S*BIO PTE LTD (SG) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114494-A1 | 8-SUBSTITUTED-2-MORPHOLINO PURINES FOR USE AS PI3K AND/OR MTOR INHIBITORS IN THE TREATMENT OF PROLIFERATIVE DISORDERS | S*BIO PTE LTD (SG) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114484-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | S*BIO PTE LTD (SG) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114484-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | S*BIO PTE LTD (SG) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044162-A1 | Fused Pyrimidine-Based Hydroxamate Derivatives | HDAC1, HDAC2, HDAC5 | PIK3CA 301/4885PIK3R1 934/4885MTOR 707/4885 |
| US-20160207927-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | DCK, CMPK1, PNP | PIK3CA 193/4885PIK3R1 909/4885MTOR 251/4885 |
| US-20170121332-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | DCK, CMPK1, PNP | PIK3CA 193/4885PIK3R1 909/4885MTOR 251/4885 |
| US-20120142683-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | DCK, CMPK1, PNP | PIK3CA 159/4885PIK3R1 824/4885MTOR 249/4885 |
| US-20180265512-A1 | FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES | HDAC1, HDAC5, HDAC2 | PIK3CA 321/4885PIK3R1 1108/4885MTOR 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.